|
|
(14 intermediate revisions by the same user not shown) |
Line 1: |
Line 1: |
| [[Idiopathic interstitial pneumonia]]
| | Ahmed Zaghw is an '''ECFMG''' -certified physician and working as an associate medical editor in '''WikiDoc''' and research fellow at '''PERFUSE Study Group''', Harvard Medical School. |
|
| |
|
| [[Sepsis resident survival guide]] | | [[File:Ahmed Zaghw,MD Wiki resolution.jpg|right]] |
|
| |
|
| [[Resident survival guide topics]]
| | ==Education== |
|
| |
|
| [[Interstitial lung disease]]
| | * '''Ain-Shams University, Cairo, Egypt''' (2003-2011) |
| | ** Baccalaureus of Medicine and Surgery MB BCh with “Excellence with Honor” |
|
| |
|
| | * '''Kentucky University, KY, USA''' |
| | ** Health care financial management and Clinical Leadership Management courses (2008) |
|
| |
|
| {{Family tree/start}}
| | ==Work Experience== |
| {{Family tree | | | | A01 |-|-|-| A02 | |A01= Stable| A02= Unstable}}
| |
| {{Family tree/end}}
| |
|
| |
|
| | * Associate medical editor in WikiDoc.(2013) |
| | * Primary care physician in Medically Underserved Districts (MUDs) (2011-2012) |
|
| |
|
| {{Family tree/start}}
| | ==Research Experience== |
| {{Family tree | | | | A01 | | | |A01= Box 1 in Row 1}}
| |
| {{Family tree | | | | |!| | | | | }}
| |
| {{Family tree | | | | B01 | | | |B01= Box 2 in Row 2}}
| |
| {{Family tree | |,|-|-|^|-|-|.| | }}
| |
| {{Family tree | C01 | | | | C02 |C01= Box 3 in Row 3| C02= Box 4 in Row 4}}
| |
| {{Family tree/end}}
| |
|
| |
|
| | * '''Kentucky University, KY, USA''' |
| | ** Research Assistant in "Forearm Wearable Artificial Kidney" (2008) |
|
| |
|
| {{Family tree/start}}
| | * '''Ain-Shams University, Cairo, Egypt''' (2008-2009) |
| {{Family tree | | C01 | | | | | | C02 | |C01= Ahmed| C02= Dzenana}}
| | ** Research trainee in Ain-Shams Stem Cell Group |
| {{Family tree/end}}
| |
|
| |
|
| | ==Awards and Affiliation== |
|
| |
|
| {|class="wikitable"
| | * '''ECFMG''' Certification (2013) |
| |lolo||lolo2||lolo3
| | * “'''Best Research Reward'''” presented by Egyptian in 18th Ainshams International Medical Students Congress (AIMSC 2009), for the oral presentation '''The role of stem cell in cardiology-many ways to one goal''' |
| |-
| | *Member of PADI, Professional American Diving Institute |
| |koko1||koko2||koko3
| | *Member of Master Swimming Team for Tanta Sports Club |
| |-
| |
| |}
| |
|
| |
|
| ---
| | ==WikiDoc contribution== |
| {|class="wikitable" width="80%"
| | * Microchapters editing in cardiology, pulmonology and critical Care |
| |lolo||lolo2||lolo3
| | :*[[Idiopathic interstitial pneumonia]] |
| |-
| | :*[[Endocarditis antimicrobial treatment]] |
| |koko1||koko2||koko3 | | :*[[Endocarditis other test]] |
| |-
| | :*[[Pericarditis treatment]] |
| |}
| | :*[[Gastrointestinal bleeding risk factors]] |
| | :*[[Cardiogenic shock diagnostic evaluation]] |
| | :*[[Atrial septal defect percutaneous closure]] |
| | * Resident Survival Guide |
| | :*[[Sepsis resident survival guide|Sepsis]] |
| | :*[[Cardiogenic shock resident survival guide]] |
| | :*[[Basic physical principles of ultrasound]] |
|
| |
|
| ----
| | *Board Review Questions |
| {|class="wikitable"width="80%"
| | :*[[WBR1033]], [[WBR1034]], [[WBR1035]], [[WBR1036]], [[WBR1037]], [[WBR1038]], [[WBR1039]], [[WBR1040]], [[WBR1041]], [[WBR1042]], [[WBR1043]], [[WBR1044]], [[WBR1045]], [[WBR1046]], [[WBR1047]], [[WBR1048]], [[WBR1049]], [[WBR1050]] |
| |-
| |
| | colspan="1" style="text-align:center; background:"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor=""|<nowiki>"</nowiki>'''1. '''High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor=|<nowiki>"</nowiki>'''2. '''In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki>
| |
| |-
| |
| |}
| |
|
| |
|
| | ==Languages== |
|
| |
|
| {|style="width:80%; height:100px" border="1"
| | *Arabic: Fluent in speaking and writing |
| |style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
| | *English: Fluent in speaking and writing |
| |style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | No underlying causes
| | *German: Very good in speaking and writing |
| |-
| |
| |bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Dental'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Dermatologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Drug Side Effect'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Ear Nose Throat'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Endocrine'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Environmental'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Gastroenterologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Genetic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Hematologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Iatrogenic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Infectious Disease'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Musculoskeletal/Orthopedic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Neurologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Nutritional/Metabolic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Obstetric/Gynecologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Oncologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Ophthalmologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Overdose/Toxicity'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Psychiatric'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Pulmonary'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Renal/Electrolyte'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Rheumatology/Immunology/Allergy'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Sexual'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Trauma'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Urologic'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |-bgcolor="LightSteelBlue"
| |
| | '''Miscellaneous'''
| |
| |bgcolor="Beige"| No underlying causes
| |
| |-
| |
| |}
| |
| <table>
| |
| {|class="wikitable" border="1" style="text-align:center; width:600px;"
| |
| |-style="background:#CDC9C9"
| |
| | Risk category
| |
| | LDL goal, mg/dL
| |
| |Non-HDL goal, mg/dL
| |
| |-
| |
| | CHD and CHD risk equivalent (10 year risk for CHD is >20%)
| |
| | < 100
| |
| | < 130
| |
| |-
| |
| | Multiple (2+) risk factor (10 year risk for CHD is <20%)
| |
| | < 130
| |
| | < 160
| |
| |-
| |
| | 0-1 risk factors
| |
| | < 160
| |
| | < 190
| |
| |-
| |
| |}
| |
|
| |
|
| ATP III LDL cholesterol and Non-HDL cholesterol goals <ref name="pmid11368702">{{cite journal| author=Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults| title=Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). | journal=JAMA | year= 2001 | volume= 285 | issue= 19 | pages= 2486-97 | pmid=11368702 | doi= | pmc= |url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11368702 }} </ref>
| | ==Contact Information== |
|
| |
|
| | E-mail address: azaghw@bidmc.harvard.edu , ahmedzaghw@wikidoc.org |
|
| |
|
| {|class="wikitable" width="80%" | | {{WikiDoc Help Menu}} |
| |-
| | {{WikiDoc Sources}} |
| | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki>
| |
| |-
| |
| | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required): <BR>
| |
| * Use high-intensity statin therapy unless contraindicated. <BR>
| |
| | |
| * For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: B]])''<nowiki>"</nowiki>
| |
| |-
| |
| |}
| |
| | |
| ==References==
| |
| {{Reflist|2}} | |